China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has formed a partnership with compatriot firm Youjia (Hangzhou) Biomedical Technology Co., Ltd to jointly develop an antibody-oligonucleotide conjugate (AOC) for the treatment of metabolic diseases. This collaboration aims to leverage the combined expertise of both companies to advance innovative therapeutic solutions in the field of metabolic disorders.
Partnership Details
The partnership between Sun-Novo and Youjia Biomedical focuses on the research and development of AOCs, a novel class of therapeutic agents that combine the targeting capabilities of antibodies with the therapeutic potential of oligonucleotides. This innovative approach holds promise for improving the treatment landscape for metabolic diseases, which affect millions of patients worldwide.-Fineline Info & Tech
Leave a Reply